{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:31:25Z","timestamp":1757777485435,"version":"3.41.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,6,1]]},"DOI":"10.2169\/internalmedicine.3743-24","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T22:11:45Z","timestamp":1729203105000},"page":"1728-1732","source":"Crossref","is-referenced-by-count":3,"title":["Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab"],"prefix":"10.2169","volume":"64","author":[{"given":"Takashi","family":"Matsumura","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Jinnouchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Kusano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yota","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Arimizu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Ohmura","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kuma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Graduate School of Medical Science, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Isobe","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ariyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Moehler M, Maderer A, Thuss-Patience PC, et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO\/EORTC trial (POWER). Ann Oncol 31: 228-235, 2020.","DOI":"10.1016\/j.annonc.2019.10.018"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 386: 449-462, 2022.","DOI":"10.1056\/NEJMoa2111380"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomized, placebo-controlled, phase 3 study. Lancet 398: 759-771, 2021.","DOI":"10.1016\/S0140-6736(21)01234-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse event associated with immune checkpoint blockade. N Engl J Med 378: 158-168, 2018.","DOI":"10.1056\/NEJMra1703481"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Khoja L, Day D, Chen TW, Siu LL, Hansen AR. Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28: 2377-2385, 2017.","DOI":"10.1093\/annonc\/mdx286"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99: 3909-3915, 2002.","DOI":"10.1182\/blood.V99.11.3909"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Satou A, Nakamura S. EBV-positive B-cell lymphomas and lymphoproliferative disorders: review from the perspective of immune escape and immunodeficiency. Cancer Med 10: 6777-6785, 2021.","DOI":"10.1002\/cam4.4198"},{"key":"8","unstructured":"8. Gaulard P, Swerdlow SH, Harris NL, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Eds. Lyon International Agency for Research on Cancer, Lyon, 2017."},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36: 1720-1748, 2022.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"10","unstructured":"10. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 18: 1741-1743, 1991."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol 42: 564-571, 2015.","DOI":"10.3899\/jrheum.140533"},{"key":"12","unstructured":"12. Kawakami A, Kuroda H, Suzuki T, et al. Angioimmunoblastic T-cell lymphoma after immune checkpoint inhibitor-combined chemotherapy for lung cancer. Rinsho Ketsueki (JPN J Clin Hematol) 63: 759-763, 2022 (in Japanese)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Anand K, Ensor J, Pingali SR, et al. T-cell lymphoma secondary to checkpoint inhibitor therapy. J Immunother Cancer 8: e000104, 2020.","DOI":"10.1136\/jitc-2019-000104"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mick JM, Lotte E, Rogier M, et al. Hematologic malignancies following immune checkpoint inhibition for solid tumors. Cancer Immunol Immunother 72: 249-255, 2023.","DOI":"10.1007\/s00262-022-03230-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Saito S, Kaneko Y, Yamamoto K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology (Oxford) 56: 940-946, 2017.","DOI":"10.1093\/rheumatology\/kex002"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91: 20-28, 2013.","DOI":"10.1111\/ejh.12116"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tokuhira M, Watanabe R, Nemoto R, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma 53: 616-623, 2012.","DOI":"10.3109\/10428194.2011.625101"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Saito S, Takeuchi T, et al. Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients. J Clin Exp Hematop 59: 145-155, 2019.","DOI":"10.3960\/jslrt.19028"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kamada T, Togashi Y, Tay C, et al. PD-1<sup>+<\/sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci 116: 9999-10008, 2019.","DOI":"10.1073\/pnas.1822001116"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yamaguchi K, Tsuchihashi K, Tsuji K, et al. Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: a case report. Medicine (Baltimore) 100: e25773, 2021.","DOI":"10.1097\/MD.0000000000025773"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Volk V, Theobald SJ, Danisch S, et al. PD-1 blockade aggravates Epstein-Barr virus<sup>+<\/sup> post transplant lymphoproliferative disorder in humanized mice resulting in central nervous system involvement and CD4<sup>+<\/sup> T Cell dysregulation. Front Oncol 10: 614876, 2020.","DOI":"10.3389\/fonc.2020.614876"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/11\/64_3743-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:38:37Z","timestamp":1749271117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/11\/64_3743-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3743-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,6,1]]},"article-number":"3743-24"}}